Free Trial
OTCMKTS:BIOVF

Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Price, News & Analysis

$25.76
0.00 (0.00%)
(As of 05/28/2024 ET)
Today's Range
$25.76
$25.76
50-Day Range
$22.87
$27.79
52-Week Range
$18.35
$27.79
Volume
N/A
Average Volume
205 shs
Market Capitalization
N/A
P/E Ratio
42.93
Dividend Yield
N/A
Price Target
N/A
BIOVF stock logo

About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

BIOVF Stock Price History

BIOVF Stock News Headlines

Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
Swedish Orphan Biovitrum AB earnings: here's what to expect
Swedish Orphan Biovitrum AB (publ) (SWOBY)
Invitation: Sobi's Q4 and FY 2023 report
Swedish Orphan Biovitrum AB BIOVF
Sobi has completed the issuances of series C shares
Reminder: Invitation: Sobi's Q3 2023 report
Invitation: Sobi's Q3 2023 report
See More Headlines
Receive BIOVF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/25/2024
Today
5/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:BIOVF
CIK
N/A
Fax
N/A
Employees
1,612
Year Founded
2001

Profitability

Net Income
$227.17 million
Pretax Margin
11.26%

Debt

Sales & Book Value

Annual Sales
$2.09 billion
Cash Flow
$1.90 per share
Book Value
$10.82 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.53

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Guido Oelkers (Age 59)
    CEO & President
    Comp: $25.82M
  • Mr. Henrik Stenqvist (Age 57)
    Chief Financial Officer
  • Mr. Torbjörn Hallberg (Age 55)
    General Counsel & Head of Legal Affairs
  • Mr. Daniel Rankin (Age 44)
    Head of Strategy & Corporate Development
  • Ms. Lena Bjurner (Age 56)
    Head of Human Resources
  • Mr. Armin Reininger M.D. (Age 67)
    Ph.D., Senior Scientific & Medical Advisor
  • Mr. Norbert Oppitz (Age 57)
    Head of International
  • Mr. Sofiane Fahmy (Age 52)
    Head of Europe
  • Mr. Duane H. Barnes (Age 64)
    Head of North America
  • Mr. Mahmood Ladha (Age 60)
    Head of Strategic Transformation Operations

BIOVF Stock Analysis - Frequently Asked Questions

Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOVF shares.
View BIOVF analyst ratings
or view top-rated stocks.

How have BIOVF shares performed in 2024?

Swedish Orphan Biovitrum AB (publ)'s stock was trading at $26.25 on January 1st, 2024. Since then, BIOVF shares have decreased by 1.9% and is now trading at $25.7557.
View the best growth stocks for 2024 here
.

Are investors shorting Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,591,500 shares, an increase of 36.9% from the April 30th total of 1,162,200 shares. Based on an average daily trading volume, of 700 shares, the days-to-cover ratio is presently 2,273.6 days.
View Swedish Orphan Biovitrum AB (publ)'s Short Interest
.

How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) released its quarterly earnings results on Thursday, April, 25th. The company reported $0.26 earnings per share (EPS) for the quarter. The firm had revenue of $601.91 million for the quarter. Swedish Orphan Biovitrum AB (publ) had a net margin of 9.29% and a trailing twelve-month return on equity of 7.92%.

How do I buy shares of Swedish Orphan Biovitrum AB (publ)?

Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BIOVF) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners